Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Standard of Care × Endocrine × Clear all

Phase

Phase NA 4 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 12 Thoracic 10 Breast 10 Gastrointestinal 9 Head & Neck 8 Other hematologic neoplasm 5 Gynecologic 4 Lymphoid 3 CNS 3 Tumor-Agnostic 2 Dermatologic 2 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 Myeloid 1 Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 25 lutetium Lu 177 dotatate 21 pembrolizumab 19 Temozolomide 18 Cisplatin 14 Magnetic Resonance Spectroscopy 13 Sunitinib 12 Nivolumab 12 lenvatinib 11 cabozantinib 11 Specimen Handling 11 Capecitabine 10 Sorafenib 9 Etoposide 9 Bevacizumab 9 trametinib 7 pasireotide 7 lanreotide 7 dabrafenib 7 Paclitaxel 7 Octreotide 7 Ipilimumab 7 Carboplatin 7 pazopanib 6 Irinotecan 6 gallium Ga 68 dotatate 5 Mitotane 5 Injections 5 Fluorodeoxyglucose F18 5 surufatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡